![]() | Up a level |
Journal Article
El-Khoueiry, Anthony B., Kim, Richard D., Harris, William P., Sung, Max W., Waldschmidt, Dirk, Iqbal, Syma, Zhang, Xiaojing (Amily), Nakajima, Keiko and Galle, Peter R. (2020). Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). J. Clin. Oncol., 38 (4). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755
El-Khoueiry, Anthony B., Kim, Richard D., Harris, William Proctor, Sung, Max W., Waldschmidt, Dirk, Cabrera, Roniel, Garosi, Vittorio Luigi, Zebger-Gong, Hong, Brennan, Barbara J., Wang, Ying A., Mueller, Udo, Ishida, Tatiane Cristine and Galle, Peter R. (2021). Updated results of a phase 1b study of regorafenib (REG) 80 mg/day or 120 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). J. Clin. Oncol., 39 (15). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755
Javle, Milind M., Roychowdhury, Sameek, Kelley, Robin Kate, Sadeghi, Saeed, Macarulla, Teresa, Waldschmidt, Dirk Thomas, Goyal, Lipika, Borbath, Ivan, El-Khoueiry, Anthony B., Yong, Wei-Peng, Philip, Philip Agop, Bitzer, Michael, Tanasanvimon, Suebpong, Pande, Amit, Shepherd, Stacie Peacock, Moran, Susan and Abou-Alfa, Ghassan K. (2021). Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement. J. Clin. Oncol., 39 (3). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755
Kim, Richard D., Harris, William P., Sung, Max W., Waldschmidt, Dirk Thomas, Cabrera, Roniel, Mueller, Udo, Menezes, Flavia, Ishida, Tatiane, Galle, Peter R. and El-Khoueiry, Anthony B. (2021). Results of a phase Ib study of regorafenib (REG) 80 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). J. Clin. Oncol., 39 (3). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. ISSN 1527-7755
Makawita, Shalini, Kelley, Robin Kate, Roychowdhury, Sameek, Weiss, Karl Heinz, Abou-Alfa, Ghassan K., Macarulla, Teresa, Sadeghi, Saeed, Waldschmidt, Dirk, Zhu, Andrew X., Goyal, Lipika, Yong, Wei-Peng, Borbath, Ivan, El-Khoueiry, Anthony B., Philip, Philip Agop, Moran, Susan, Ye, Yining, Soifer, Harris S., Li, Gary, Berman, Craig and Javle, Milind M. (2020). Circulating free DNA (cfDNA) and tissue next-generation sequencing analysis in a phase II study of infigratinib (BGJ398) for cholangiocarcinoma with FGFR2 fusions. J. Clin. Oncol., 38 (4). ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755